文献速递外周动脉疾病

低剂量第二代Ranger药物涂层球囊血管成形术治疗股腘动脉疾病的临床结局

Clinical Outcomes Following Low-Dose Second-Generation "Ranger" Drug-Coated Balloon Angioplasty for Femoropopliteal Artery Disease.
PubMed 文献 · J Endovasc Ther · 2024-11-21

这项多中心前瞻性观察研究纳入1131例患者共1453处股腘动脉病变,在2021年3月至2022年12月间接受Ranger药物涂层球囊血管成形术。1年免于再狭窄率为85.2%,免于靶病变血运重建率为91.7%。再狭窄的独立危险因素包括女性、糖尿病、无流出道、既往血运重建史、病变长度≥25 cm和慢性完全闭塞。

要点

  • Ranger药物涂层球囊治疗后1年免于再狭窄率为85.2%,免于靶病变血运重建率为91.7%。
  • 再狭窄形态以闭塞性(31.3%)和局限性(39.2%)为主,非闭塞性形态占三分之二。
  • 再狭窄独立危险因素包括女性、糖尿病、无流出道、既往血运重建史、病变长度≥25 cm和慢性完全闭塞。

核心结论

  • 在真实世界临床环境中,Ranger药物涂层球囊治疗股腘动脉病变的1年免于再狭窄率是可接受的。
  • 再狭窄的独立预测因素为女性、糖尿病、无流出道、既往血运重建史、病变长度≥25 cm和慢性完全闭塞。

研究设计与样本

  • 多中心、前瞻性观察性研究,纳入1131例患者共1453处新发或再狭窄股腘动脉病变,平均年龄75±9岁,女性占35.3%,平均病变长度19.2±16.0 cm,慢性完全闭塞占33.7%,严重钙化占33.7%。
  • 患者于2021年3月至2022年12月间接受Ranger药物涂层球囊血管成形术。

主要发现

  • 补救性支架置入率为5.3%。
  • 随访期间检出249例再狭窄。
  • Kaplan-Meier分析估计12个月和14个月免于再狭窄率分别为85.2%和81.0%。
  • 12个月和14个月免于靶病变血运重建率分别为91.7%和90.0%。
  • 再狭窄形态为局限性39.2%、串联型12.3%、弥漫型17.2%和闭塞性31.3%。

关键数值与推荐

  • 再狭窄独立危险因素:女性、糖尿病、无流出道、既往血运重建史、病变长度≥25 cm和慢性完全闭塞。
  • 临床影响部分报告1年免于再狭窄率和免于靶病变血运重建率分别为84.5%和91.5%,与结果部分报告的85.2%和91.7%不一致,原文未解释。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To reveal the rate of 1-year freedom from restenosis and to determine the factors associated with the restenosis risk in femoropopliteal (FP) lesions treated with a Ranger drug-coated balloon (DCB) in real-world clinical settings. METHODS: This multicenter, prospective observational study enrolled 1131 patients and 1453 de novo or restenotic FP lesions (mean age=75±9 years; female=35.3%, mean lesion length=19.2±16.0 cm; chronic total occlusion [CTO]=33.7%; severe calcification=33.7%) that underwent successful Ranger DCB angioplatsy between March 2021 and December 2022. RESULTS: The primary endpoint was 1-year freedom from restenosis and its associated factors. Bail-out stenting was performed in 5.3%. During the follow-up, restenosis was detected in 249 cases. Freedom from restenosis by the Kaplan-Meier analysis was estimated to be 85.2% and 81.0% at 12 and 14 months, whereas freedom from target lesion revascularization (TLR) was 91.7% and 90.0% at 12 and 14 months. The patterns of restenosis were focal (39.2%), tandem (12.3%), diffuse (17.2%), and occlusive (31.3%). Independent risk factors of restenosis were female sex, diabetes mellitus, no runoff, history of revascularization, lesion length ≥25 cm, and CTO. CONCLUSIONS: Our study demonstrated that 1-year freedom from restenosis after Ranger DCB for FP lesions in a real-world clinical setting was acceptable. Independent predictors of restenosis were female gender, diabetes mellitus, no runoff, history of revascularization, lesion length ≥25 cm, and CTO.Clinical ImpactOur study demonstrated the true performance of Ranger DCB in real-world practice, with a very low rate of bail-out stenting and no use of atherectomy devices. In addition, it also elucidated morphologies associated with restenosis and the risk factors for restenosis after DCB. Freedom from re-stenosis and TLR at 1-year after Range DCB angioplasty was 84.5% and 91.5%. Two thirds of restenosis had a non-occlusive pattern, and independent predictors of restenosis were female gender, diabetes mellitus, no runoff, history of revascularization, lesion length ≥25 cm, and CTO.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Soga Y, Takahara M, Iida O, et al. Clinical Outcomes Following Low-Dose Second-Generation "Ranger" Drug-Coated Balloon Angioplasty for Femoropopliteal Artery Disease. J Endovasc Ther. 2024. PMID: 39569626. doi:10.1177/15266028241292464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。